Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN Turkoglu, Recai/0000-0001-9724-851X; Altintas, Ayse/0000-0002-8524-5087; WOS: 000485303100108 … European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd EMD SeronoMerck Serono; NovartisNovartis; Bayer ScheringBayer AG; BiogenBiogen; MerckMerck & Company; Sanofi AventisSanofi-Aventis; Teva; Czech Ministry of EducationMinistry of Education, Youth & Sports - Czech Republic [Q27/LF1] Eva Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1]. Francesco Patti FP served on advisory board meeting Almirall, Bayer, Biogen, Celgene, Merck, Myalin, Novartis, Roche, Sanofi and TEVA. He also received speaking honoraria by Almirall, Biogen, Merck, Novartis, Roche, Sanofi and TEVA; research grants by Biogen and Merck, Fondazione Italiana Sclerosi Multipla, RLOAD Onlus, Ministero della Ricerca Scientifica and University of CataniaFranco Granella received an institutional research grant from Biogen and Sanofi Genzyme, served on scientific advisory boards for Biogen, Novartis, Merck, Sanofi Genzyme and Roche, received funding for travel and speaker honoraria from Biogen, Merck, and Sanofi-Aventis. Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals. Fraser Moore participated in clinical trials sponsored by EMD Serono and Novartis. Freek Verheul is an advisory board member for Teva Biogen Merck and Novartis. Gerardo Iuliano had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva. Helmut Butzkueven Institution (Monash university) has received compensation for consulting, talks, advisory/steering board activities from Biogen, Merck, Novartis, Genzyme, Alfred Health; research support from Novartis, Biogen, Roche, Merck, NHMRC, Pennycook Foundation, MSRA. HB has received compensation for same activities from Oxford Health Policy Forum, Merck, Biogen, Novartis. Jeannette Lechner-Scott accepted travel compensation from Novartis, Biogen and Merck. Her institution receives the honoraria for talks and advisory board commitment from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis and Teva, has been involved in clinical trials with Biogen, Novartis and Teva. Jens Kuhle Jens Kuhle did not declare any competing interests. JosA (c) Luis SAnchez Menoyo accepted travel compensation from Novartis and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in a clinical trial by Biogen. Juan Ignacio Rojas did not declare any competing interests. Julie Prevost accepted travel compensation from Novartis, Biogen, Genzyme, Teva, and speaking honoraria from Biogen, Novartis, Genzyme and Teva. Marco Onofrj did not declare any competing interestsMaria edite Rio did not declare any competing interests. Maria Jose Sa has received consulting fees from Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva. Maria Laura Saladino did not declare any competing interests. Mark Slee has participated in, but not received honoraria for, advisory board activity for Biogen, Merck, Bayer Schering, Sanofi Aventis and Novartis. Mark Slee has participated in, but not received honoraria for, advisory board activity for Biogen, Merck, Bayer Schering, Sanofi Aventis and Novartis. Michael Barnett served on scientific advisory boards for Biogen, Novartis and Genzyme and has received conference travel support from Biogen and Novartis. He serves on steering committees for trials conducted by Novartis. His institution has received research support from Biogen, Merck and Novartis. Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.; Norma Deri received funding from Bayer, Merck, Biogen, Genzyme and Novartis. Pamela McCombe did not declare any competing interestspatrizia sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva. Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme. Pierre Grammond is a Merck, Novartis, Tevaneuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis. Radek Ampapa received conference travel support from Novartis, Teva, Biogen, Bayer and Merck and has participated in a clinical trials by Biogen, Novartis, Teva and Actelion. Raed Alroughani received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme. Raymond Hupperts received honoraria as consultant on scientific advisory boards from Merck, Biogen, Genzyme-Sanofi and Teva, research funding from Merck and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis. Recai Turkoglu did not declare any competing interests. Riadh Gouider did not declare any competing interests. Ricardo Fernandez Bolanos received speaking honoraria from Biogen, Novartis, Merck and Teva. Roberto Bergamaschi received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva. Sara Eichau did not declare any competing interests. Serkan Ozakbas did not declare any competing interests. Shlomo Flechter received research funding, speaker honoraria and compensation for travel from and served as a consultant on advisory board for Bayer-Schering, Teva, Biogen, Merck, Genzyme and Novartis. Steve Vucic did not declare any competing interestsTamara Castillo TriviA +/- o did not declare any competing interests. Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, GenzymeSanofi, Teva, BioCSL and Merck and received research support from Biogen. Tunde Csepany received speaker honoraria/conference travel support from Bayer Schering, Biogen, Merck, Novartis, Roche, Sanofi-Aventis and Teva. Vahid Shaygannejad did not declare any competing interests. Vincent Van Pesch received travel grants from Biogen, Sanofi, Roche, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Sanofi, Roche, Merck, Roche, Teva and Novartis Pharma, as well as research grants from Roche, Sanofi and Novartis Pharma.